ALC Stock Recent News

New product launches and strong solvency bode well for Alcon (ALC).

Here is how Alcon (ALC) and CalciMedica Inc. (CALC) have performed compared to their sector so far this year.

ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (TSX: ALC) (TSX: ALC.DB.A) announced today that following the second quarter dividend of $0.19 per common share, an adjustment has been made to the conversion price of the convertible debentures, reducing it to $14.10. The convertible debentures have a maturity date of June 30, 2024. The second quarter dividend will be paid on June 3, 2024 to shareholders of record on May 17, 2024. About Algoma Central Corporation Algoma Centr.

Alcon's (ALC) Q1 results reflect substantial growth in its franchises on the back of healthy markets.

Alcon Inc. (NYSE:ALC ) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Graham Doyle - UBS Veronica Dubajova - Citi Ryan Zimmerman - BTIG Richard Felton - Goldman Sachs Larry Biegelsen - Wells Fargo Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Co Michael Sarcone - Jefferies Brett Fishbin - KeyBanc Capital Markets Anthony Petrone - Mizuho Group Issie Kirby - Redburn Atlantic Tom Stephan - Stifel Operator Greetings, and welcome to the Alcon's First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alcon (ALC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).

Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).

Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.